Immuron Limited (IMRN)

[Kauri]

Sanyal is quoted as stating:

"This is truly a proof of concept for this first-in-class drug candidate." said Arun Sanyal, Professor of Gastroenterology and Hepatology from the Virginia Commonwealth University in Richmond, USA and the study lead Principle Investigator.

"The IMM-124E drug candidate has been developed to target LPS in the gut and prevent it translocating into the portal circulation. The study results clearly demonstrate a statistically significant reduction of serum LPS levels in the treatment groups when compared to placebo and provides us with a proof of concept that metabolic endotoxemia can indeed be decreased using this drug candidate (IMM-124E) which targets the endotoxin LPS. We are encouraged that IMM-124E, a drug with an exceptional safety profile, can lower the LPS-associated inflammatory burden and improve liver enzymes. The potential clinical applications for this drug candidate are numerous and very exciting indeed"